An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron [peginterferon alfa-2b] in naive Patients With Chronic Hepatitis B and D co-Infection.
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 10 Jun 2017 Biomarkers information updated
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2008 Planned patient number (67) added as reported by ClinicalTrials.gov.